炭疽疫苗的现状及未来关键研发差距
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward.
作者信息
Clark Adam, Wolfe Daniel N
机构信息
Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Assistant Secretary for Preparedness and Response, Washington, DC, USA.
出版信息
Microorganisms. 2020 Apr 29;8(5):651. doi: 10.3390/microorganisms8050651.
Abstract
A licensed anthrax vaccine has been available for pre-exposure prophylaxis in the United States since 1970, and it was approved for use as a post-exposure prophylaxis, in combination with antibiotic treatment, in 2015. A variety of other vaccines are available in other nations, approved under various regulatory frameworks. However, investments in anthrax vaccines continue due to the severity of the threat posed by this bacterium, as both a naturally occurring pathogen and the potential for use as a bioweapon. In this review, we will capture the current landscape of anthrax vaccine development, focusing on those lead candidates in clinical development. Although approved products are available, a robust pipeline of candidate vaccines are still in development to try to address some of the key research gaps in the anthrax vaccine field. We will then highlight some of the most pressing needs in terms of anthrax vaccine research.
摘要
自1970年以来，美国就有了一种获得许可的炭疽疫苗用于暴露前预防，2015年它被批准与抗生素治疗联合用于暴露后预防。其他国家有多种其他疫苗，在不同的监管框架下获得批准。然而，由于这种细菌作为自然存在的病原体以及作为生物武器使用的可能性所构成威胁的严重性，对炭疽疫苗的投资仍在继续。在本综述中，我们将介绍炭疽疫苗研发的当前情况，重点关注临床研发中的那些领先候选疫苗。尽管已有获批产品，但仍有一系列强大的候选疫苗正在研发中，以试图填补炭疽疫苗领域的一些关键研究空白。然后，我们将强调炭疽疫苗研究方面一些最紧迫的需求。
相似文献
1
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward.炭疽疫苗的现状及未来关键研发差距
Microorganisms. 2020 Apr 29;8(5):651. doi: 10.3390/microorganisms8050651.
2
Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule.生物炭疽疫苗暴露前和暴露后预防的许可策略：首个依据美国食品药品监督管理局动物规则获批的疫苗。
Expert Rev Vaccines. 2016 Dec;15(12):1467-1479. doi: 10.1080/14760584.2016.1254556.
3
Vaccines and bioterrorism: smallpox and anthrax.疫苗与生物恐怖主义：天花与炭疽
J Fam Pract. 2003 Jan;52(1 Suppl):S56-61.
4
Vaccines: countering anthrax: vaccines and immunoglobulins.疫苗：对抗炭疽：疫苗与免疫球蛋白
Clin Infect Dis. 2008 Jan 1;46(1):129-36. doi: 10.1086/523578.
5
Anthrax Vaccines in the 21st Century.21世纪的炭疽疫苗
Vaccines (Basel). 2024 Feb 3;12(2):159. doi: 10.3390/vaccines12020159.
6
Prophylaxis against anthrax.炭疽预防
Acta Medica (Hradec Kralove). 2002;45(3):85-8.
7
Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax.抵御生物恐怖主义的成本效益：炭疽疫苗接种与抗生素预防的比较
Ann Intern Med. 2005 Apr 19;142(8):601-10. doi: 10.7326/0003-4819-142-8-200504190-00008.
8
Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.应对恐怖主义时炭疽疫苗的使用：免疫实践咨询委员会的补充建议
MMWR Morb Mortal Wkly Rep. 2002 Nov 15;51(45):1024-6.
9
Current Status and Trends in Prophylaxis and Management of Anthrax Disease.炭疽病预防与管理的现状及趋势
Pathogens. 2020 May 12;9(5):370. doi: 10.3390/pathogens9050370.
10
Stability and pre-formulation development of a plant-produced anthrax vaccine candidate.一种植物生产的炭疽候选疫苗的稳定性和处方前研究
Vaccine. 2017 Oct 4;35(41):5463-5470. doi: 10.1016/j.vaccine.2016.12.009. Epub 2017 Jan 20.
引用本文的文献
1
A Lyophilizable Nanoparticle Vaccine Specific for a Novel Linear Neutralizing Epitope in the α2-α3 Helices of Domain 3 of Lethal Factor from .一种针对来自致死因子第3结构域α2-α3螺旋中新型线性中和表位的冻干纳米颗粒疫苗。
Toxins (Basel). 2025 Aug 20;17(8):422. doi: 10.3390/toxins17080422.
2
Biological threat preparedness through vaccine development and stockpiling: challenges and strategic implications.通过疫苗研发和储备实现生物威胁防范：挑战与战略影响
Front Public Health. 2025 Jun 2;13:1614626. doi: 10.3389/fpubh.2025.1614626. eCollection 2025.
3
Are we ready for the next anthrax outbreak? Lessons from a simulation exercise in a rural-based district in Uganda.我们准备好应对下一次炭疽疫情了吗？来自乌干达一个农村地区模拟演练的经验教训。
Epidemiol Infect. 2024 Dec 2;152:e151. doi: 10.1017/S0950268824001493.
4
Anthrax: A narrative review.炭疽：一篇叙述性综述。
New Microbes New Infect. 2024 Oct 10;62:101501. doi: 10.1016/j.nmni.2024.101501. eCollection 2024 Dec.
5
Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.5型分泌系统抗原作为抗革兰氏阴性菌感染的疫苗
NPJ Vaccines. 2024 Sep 1;9(1):159. doi: 10.1038/s41541-024-00953-6.
6
Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform.T4 噬菌体作为一种基于蛋白质的、无佐剂和无针的黏膜大流行疫苗设计平台。
Annu Rev Virol. 2024 Sep;11(1):395-420. doi: 10.1146/annurev-virology-111821-111145. Epub 2024 Aug 30.
7
Anthrax Vaccines in the 21st Century.21世纪的炭疽疫苗
Vaccines (Basel). 2024 Feb 3;12(2):159. doi: 10.3390/vaccines12020159.
8
Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics.开发一种新的基于细胞的 AP-1 基因报告基因效力测定法，用于抗炭疽毒素治疗药物。
Toxins (Basel). 2023 Aug 28;15(9):528. doi: 10.3390/toxins15090528.
9
Human Anthrax: Update of the Diagnosis and Treatment.人类炭疽病：诊断与治疗的最新进展
Diagnostics (Basel). 2023 Mar 10;13(6):1056. doi: 10.3390/diagnostics13061056.
10
Beyond the spore, the exosporium sugar anthrose impacts vegetative Bacillus anthracis gene regulation in cis and trans.除孢子外，外孢糖 anthrose 影响有荚膜炭疽杆菌的顺式和反式营养期基因调控。
Sci Rep. 2023 Mar 28;13(1):5060. doi: 10.1038/s41598-023-32162-x.
本文引用的文献
1
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019.美国炭疽疫苗的使用：免疫实践咨询委员会的建议，2019 年。
MMWR Recomm Rep. 2019 Dec 13;68(4):1-14. doi: 10.15585/mmwr.rr6804a1.
2
Medical Spending for the 2001 Anthrax Letter Attacks.2001 年炭疽信件袭击的医疗支出。
Disaster Med Public Health Prep. 2019 Jun;13(3):539-546. doi: 10.1017/dmp.2018.113. Epub 2018 Nov 12.
3
Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.炭疽疫苗沉淀剂可诱导人类接种者产生中和水肿毒素、针对水肿因子的特异性抗体。
Clin Vaccine Immunol. 2017 Nov 6;24(11). doi: 10.1128/CVI.00165-17. Print 2017 Nov.
4
Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.用候选AV7909炭疽疫苗接种的豚鼠和非人灵长类动物中，炭疽致死毒素中和抗体水平与存活率之间的相关性。
Vaccine. 2017 Sep 5;35(37):4952-4959. doi: 10.1016/j.vaccine.2017.07.076. Epub 2017 Jul 31.
5
Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.致死因子抗体有助于中和炭疽疫苗沉淀接种者体内的致死毒素。
Vaccine. 2017 Jun 8;35(26):3416-3422. doi: 10.1016/j.vaccine.2017.05.006. Epub 2017 May 11.
6
Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events.可能暴露于炭疽杆菌后的暴露后预防：用药依从性和不良事件。
Health Secur. 2016 Nov/Dec;14(6):419-423. doi: 10.1089/hs.2016.0060. Epub 2016 Nov 29.
7
Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.一项随机、双盲、活性对照研究，评估三种接种方案和两种剂量水平的AV7909疫苗对健康成年人炭疽暴露后预防的安全性和免疫原性。
Vaccine. 2016 Apr 19;34(18):2096-105. doi: 10.1016/j.vaccine.2016.03.006. Epub 2016 Mar 12.
8
Russian vaccines against especially dangerous bacterial pathogens.针对特别危险的细菌病原体的俄罗斯疫苗。
Emerg Microbes Infect. 2014 Dec;3(12):e86. doi: 10.1038/emi.2014.82. Epub 2014 Dec 17.
9
Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.18至20岁人群中炭疽疫苗安全性评估：迈向青少年年龄递减研究的第一步。
Vaccine. 2015 May 15;33(21):2470-6. doi: 10.1016/j.vaccine.2015.03.071. Epub 2015 Apr 5.
10
Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.在雾化孢子兔攻击模型中，单剂量腺病毒载体鼻内炭疽疫苗与吸附型炭疽疫苗相比的有效性和免疫原性。
Clin Vaccine Immunol. 2015 Apr;22(4):430-9. doi: 10.1128/CVI.00690-14. Epub 2015 Feb 11.
Zotero 插件